J. Söllner(1), P. Mayer(1), A. Heinzel(1), R. Fechete(1), C. Siehs(1), R. Oberbauer(2,3), B. Mayer(1,4)
1- emergentec biodevelopment GmbH, Vienna, Austria
2- Department of Nephrology Medical University of Vienna, Austria
3- Department of Nephrology KH Elisabethinen, Linz, Austria
4- Department of Theoretical Chemistry, University of Vienna, Austria
Pairwise gene level overlap of relevant KEGG pathways in % gene content of compared pathways (pw1 and pw2, respectively).
View PDFSelected clinical trials showing association of MMF with diseases suggested to be associated with MMF molecular footprint by synlet enrichment between or within pathways. Only the drug association determined by synlet associated pathways is indicated, even if multiple drugs are used in a trial (as is often the case). Importantly, few trials were designed to differentiate MMF use from other drug combinations, yet apply MMF as part of basic treatment or within a list of potential treatment options.
View PDFThis table summarizes discussed application potentials for MMF based on pathway analysis, explicit synlet network and existing clinical use. This list does not present all possibly synergistic drug combinations, only those for which certain experimental or clinical evidence exists or where extension of existing practice seems to be particularly interesting. Also, this compilation is not a complete representation of current MMF applications, particularly as it has been used in allograft transplantation and numerous auto-immune disorders to some degree.
View PDFPotential effects of drug combinations suggested by the MMF synlet graph with or without addition of MMF. This table summarizes a number of potential interactions pointed out in the manuscript although searching for MMF independent interactions and effects of alleles was not focus of the study.
View PDF